AI Article Synopsis
- - This year in rheumatology has seen advancements in understanding rheumatoid arthritis and low back pain mechanisms, improving diagnosis and management strategies.
- - Key studies were released on gout, axial spondyloarthritis, autoinflammatory diseases, and systemic vasculitides, along with updated treatment guidelines from ASAS-EULAR and EULAR/PReS.
- - New safety data on JAK inhibitors emerged, as well as innovative glucocorticoid-sparing strategies for treating giant cell arteritis.
Article Abstract
In rheumatology, this year has been characterized by a broader knowledge of the pathogenesis of rheumatoid arthritis and mechanisms involved in the onset and persistence of low back pain. Studies relevant to the management of of gout, axial spondyloarthritis, autoinflammatory diseases and systemic vasculitides were published. New data on the safety of JAK inhibitors have been published. The ASAS-EULAR recommendations for the treatment of axial spondyloarthritis were updated, and the 2023 EULAR/PReS guidelines for the diagnosis and treatment of systemic juvenile idiopathic arthritis and adult-onset Still's disease are now available. New molecules and different glucocorticoid sparing strategies were introduced for giant cell arteritis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2024.20.856-7.102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!